Implementation of GeneXpert for TB Testing in Low- and Middle-Income Countries: A Systematic Review

Scott Brown, Justine E Leavy, Jonine Jancey, Scott Brown, Justine E Leavy, Jonine Jancey

Abstract

Introduction: Current evidence indicates that the impact of GeneXpert for diagnosing TB in low- and middle-income countries (LMICs) has not demonstrated equivalent outcomes when compared to Xpert evaluations in upper-middle-income countries. Challenges associated with implementation are possible contributing factors preventing this innovative diagnostic technology from achieving more significant public health outcomes. This review aimed to assess the use of implementation science frameworks when reporting the enablers and barriers for the implementation of GeneXpert for diagnosing TB in LMICs.

Methods: We conducted a qualitative systematic review of the peer-reviewed literature using PubMed, Medline, and Scopus. Eligible articles were those published between January 2010 and March 2020 that identified enablers and barriers to GeneXpert implementation, as well as the implementation approach delivered in an LMIC.

Results: Eleven studies were included in the review. Implementation barriers were found to be relatively consistent across studies and included patient-level factors, human resources, material resources, service implementation, service coordination, and technical operations. Few studies (n=5) identified enabling factors in the implementation of Xpert for TB testing. Identified enablers included strategies such as active case finding, expanding diagnostic algorithms, and daily transport of samples. The public health impact of Xpert TB testing interventions was commonly influenced by implementation barriers (n=4). Of the 11 studies, only 3 reported against an implementation framework.

Conclusion: This review identified a commonality in implementation barriers and enablers that influenced the overall public health impact of GeneXpert. With greater transparency of these barriers and enablers, program planners can promote a more collaborative approach and adapt interventions. It is recommended that program planners use implementation science frameworks when conducting research and publishing. This will build an evidence base focused on implementation and thereby support programs to address implementation barriers and include enabling factors in program design.

© Brown et al.

Figures

FIGURE
FIGURE
PRISMA Flow Chart for Study Selection on Implementation of GeneXpert for TB Testing in Low- and Middle-Income Countries Abbreviation: PRISMA, Preferred Reporting Items for Systematic reviews and Meta-Analyses.

References

    1. World Health Organization (WHO). Global Tuberculosis Report 2020. WHO; 2020. Accessed August 10, 2021.
    1. World Health Organization. Tuberculosis. October 14, 2020. Accessed August 10, 2021.
    1. Stevens WS, Scott L, Noble L, Gous N, Dheda K. Impact of the GeneXpert MTB/RIF technology on tuberculosis control. Microbiol Spectr. 2017;5(1). 10.1128/microbiolspec.TBTB2-0040-2016.
    1. Lavu EK, Johnson K, Banamu J, et al. . Drug-resistant tuberculosis diagnosis since Xpert ® MTB/RIF introduction in Papua New Guinea, 2012–2017. Public Health Action. 2019;9(Suppl 1):S12–S18. 10.5588/pha.19.0005.
    1. Hanrahan CF, Haguma P, Ochom E, et al. . Implementation of Xpert MTB/RIF in Uganda: missed opportunities to improve diagnosis of tuberculosis. Open Forum Infect Dis. 2016;3(2):ofw068. 10.1093/ofid/ofw068.
    1. The End TB Strategy. World Health Organization website. Accessed August 10, 2021.
    1. Lawn SD, Nicol MP. Xpert® MTB/RIF assay: development, evaluation and implementation of a new rapid molecular diagnostic for tuberculosis and rifampicin resistance. Future Microbiol. 2011;6(9):1067–1082. 10.2217/fmb.11.84.
    1. Khaparde S, Raizada N, Nair SA, et al. . Scaling-up the Xpert MTB/RIF assay for the detection of tuberculosis and rifampicin resistance in India: an economic analysis. PLoS One. 2017;12(9):e0184270. 10.1371/journal.pone.0184270.
    1. Lewandrowski EL, Lewandrowski K. Implementing point-of-care testing to improve outcomes. J Hosp Adm. 2013;2(2):125. 10.5430/jha.v2n2p125
    1. Pai NP, Vadnais C, Denkinger C, Engel N, Pai M. Point-of-care testing for infectious diseases: diversity, complexity, and barriers in low- and middle-income countries. PLoS Med. 2012;9(9):e1001306. 10.1371/journal.pmed.1001306.
    1. Hamilton DO, Vas Nunes J, Grobusch MP. Improving the diagnostics of tuberculosis and drug resistance with Xpert MTB/RIF in a district general hospital in Sierra Leone: a quality improvement project. BMJ Open Qual. 2019;8(2):e000478. 10.1136/bmjoq-2018-000478.
    1. World Health Organization (WHO). Xpert MTB/RIF Assay for the Diagnosis of TB: Meeting Report. WHO; 2016. Accessed August 10, 2021.
    1. Creswell J, Codlin AJ, Andre E, et al. . Results from early programmatic implementation of Xpert MTB/RIF testing in nine countries. BMC Infect Dis. 2014;14(1):2. 10.1186/1471-2334-14-2.
    1. Piatek AS, Van Cleeff M, Alexander H, et al. . GeneXpert for TB diagnosis: planned and purposeful implementation. Glob Health Sci Pract. 2013;1(1):18–23. 10.9745/GHSP-D-12-00004.
    1. Cattamanchi A, Berger CA, Shete PB, et al. . Implementation science to improve the quality of tuberculosis diagnostic services in Uganda. J Clin Tuberc Other Mycobact Dis. 2019;18:100136. 10.1016/j.jctube.2019.100136.
    1. Di Tanna GL, Khaki AR, Theron G, et al. . Effect of Xpert MTB/RIF on clinical outcomes in routine care settings: individual patient data meta-analysis. Lancet Glob Health. 2019;7(2):e191–e199. 10.1016/S2214-109X(18)30458-3.
    1. Moyenga I, Roggi A, Sulis G, et al. . The impact of Xpert ® MTB/RIF depends on service coordination: experience in Burkina Faso. Int J Tuberc Lung Dis. 2015;19(3):285–287. 10.5588/ijtld.14.0629.
    1. Piatek AS, Wells WA, Shen KC, Colvin CE. Realizing the “40 by 2022” commitment from the United Nations high-level meeting on the fight to end tuberculosis: what will it take to meet rapid diagnostic testing needs? Glob Health Sci Pract. 2019;7(4):551–563. 10.9745/GHSP-D-19-00244.
    1. Kip MMA, Hummel JM, Eppink EB, et al. . Understanding the adoption and use of point-of-care tests in Dutch general practices using multi-criteria decision analysis. BMC Fam Pract. 2019;20(1):8. 10.1186/s12875-018-0893-4.
    1. Theobald S, Brandes N, Gyapong M, et al. . Implementation research: new imperatives and opportunities in global health. Lancet. 2018;392(10160):2214–2228. 10.1016/S0140-6736(18)32205-0.
    1. Eccles MP, Mittman BS. Welcome to implementation science. Implement Sci. 2006;1(1):1. 10.1186/1748-5908-1-1
    1. Peters DH, Adam T, Alonge O, Agyepong IA, Tran N. Republished research: Implementation research: what it is and how to do it. Br J Sports Med. 2014;48(8):731–736. 10.1136/bmj.f6753.
    1. Damschroder LJ, Aron DC, Keith RE, Kirsh SR, Alexander JA, Lowery JC. Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science. Implement Sci. 2009;4(1):50. 10.1186/1748-5908-4-50.
    1. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. 10.1371/journal.pmed.1000097.
    1. The World Bank Group. World Bank Country and Lending Groups. Accessed August 10, 2021.
    1. Cowan J, Michel C, Manhiça I, et al. . Implementing rapid testing for tuberculosis in Mozambique. Bull World Health Organ. 2015;93(2):125–130. 10.2471/BLT.14.138560.
    1. Sikhondze W, Dlamini T, Khumalo D, et al. . Countrywide roll-out of Xpert(®) MTB/RIF in Swaziland: the first three years of implementation. Public Health Action. 2015;5(2):140–146. 10.5588/pha.15.0001.
    1. Nalugwa T, Shete PB, Nantale M, et al. . Challenges with scale-up of GeneXpert MTB/RIF® in Uganda: a health systems perspective. BMC Health Serv Res. 2020;20(1):162. 10.1186/s12913-020-4997-x.
    1. Newtonraj A, Venables E, Selvaraj K, et al. . Xpert negative means no TB: a mixed-methods study into early implementation of Xpert in Puducherry, India. J Family Med Prim Care. 2019;8(4):1379–1385. 10.4103/jfmpc.jfmpc_421_18.
    1. Rendell NL, Bekhbat S, Ganbaatar G, Dorjravdan M, Pai M, Dobler CC. Implementation of the Xpert MTB/RIF assay for tuberculosis in Mongolia: a qualitative exploration of barriers and enablers. PeerJ. 2017;5(7):e3567. 10.7717/peerj.3567.
    1. Gidado M, Nwokoye N, Nwadike P, et al. . Unsuccessful Xpert ® MTB/RIF results: the Nigerian experience. Public Health Action. 2018;8(1):2–6. 10.5588/pha.17.0080.
    1. Hoang TTT, Nguyen NV, Dinh SN, et al. . Challenges in detection and treatment of multidrug resistant tuberculosis patients in Vietnam. BMC Public Health. 2015;15(1):980. 10.1186/s12889-015-2338-5.
    1. Joshi B, Lestari T, Graham SM, et al. . The implementation of Xpert MTB/RIF assay for diagnosis of tuberculosis in Nepal: a mixed-methods analysis. PLoS One. 2018;13(8):e0201731. 10.1371/journal.pone.0201731.
    1. Mustapha G, et al. . Assessment of Gene-Xpert MTB/RIF program implementation and the challenges for enhanced tuberculosis diagnosis in Nigeria. SAARC J Tuberc Lung Dis HIV/AIDS. 2015;12(2):1–7. 10.3126/saarctb.v12i2.15948
    1. Awan WM, Zaidi SMA, Habib SS, et al. . Impact of scaling up Xpert ® MTB/RIF testing for the detection of rifampicin-resistant TB cases in Karachi, Pakistan. Int J Tuberc Lung Dis. 2018;22(8):899–904. 10.5588/ijtld.17.0729.
    1. Elrod JK, Fortenberry JL., Jr.The hub-and-spoke organization design: an avenue for serving patients well. BMC Health Serv Res. 2017;17(Suppl 1):457. 10.1186/s12913-017-2341-x.
    1. Dominique JK, Ortiz-Osorno AA, Fitzgibbon J, et al. . Implementation of HIV and tuberculosis diagnostics: the importance of context. Clin Infect Dis. 2015;61Suppl 3(Suppl 3):S119–S125. 10.1093/cid/civ552.
    1. Pantoja T, Opiyo N, Lewin S, et al. . Implementation strategies for health systems in low-income countries: an overview of systematic reviews. Cochrane Database Syst Rev. 2017;9(9):CD011086. 10.1002/14651858.CD011086.pub2.
    1. Katoba J, Kuupiel D, Mashamba-Thompson TP. Toward improving accessibility of point-of-care diagnostic services for maternal and child health in low- and middle-income countries. Point Care. 2019;18(1):17–25. 10.1097/POC.0000000000000180.
    1. Pinnock H, Barwick M, Carpenter CR, et al. ; StaRI Group. Standards for Reporting Implementation Studies (StaRI) statement. BMJ. 2017;356:i6795. 10.1136/bmj.i6795.
    1. Keith RE, Crosson JC, O’Malley AS, Cromp D, Taylor EF. Using the Consolidated Framework for Implementation Research (CFIR) to produce actionable findings: a rapid-cycle evaluation approach to improving implementation. Implement Sci. 2017;12(1):15. 10.1186/s13012-017-0550-7.
    1. Lobb R, Colditz GA. Implementation science and its application to population health. Annu Rev Public Health. 2013;34(1):235–251. 10.1146/annurev-publhealth-031912-114444.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir